Gateway Pharmaceutical

Gateway Pharmaceutical is a biotechnology company headquartered in St. Louis, Missouri, focused on developing site-specific delivery technologies for existing pharmaceutical agents. The company utilizes a proprietary colon-specific delivery platform to improve the treatment of gastrointestinal and infectious diseases, primarily targeting the 505(b)(2) regulatory pathway. Its lead candidate, Metronidazole Delayed-Release Capsules, is designed to treat Clostridioides difficile infection (CDI) by providing high local drug concentrations in the colon while maintaining low systemic exposure to reduce side effects. Gateway has successfully completed a Phase 1 clinical trial for this program and has been supported by non-dilutive funding from the NIH and BioSTL's BioGenerator. The company's pipeline also includes early-stage programs for other colonic and infectious conditions using the same targeted delivery technology.